Hillsdale Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hillsdale Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-42,220	Closed	-$3.89M	–	679
2021 Q1	$3.89M	Sell	42,220 -30	-0.1%	-$2.53K	0.33%	104
2020 Q4	$3.09M	Sell	42,250 -12,300	-23%	-$914K	0.29%	121
2020 Q3	$4.24M	Sell	54,550 -24,450	-31%	-$1.68M	0.42%	53
2020 Q2	$4.39M	Sell	79,000 -47,700	-38%	-$2.04M	0.4%	55
2020 Q1	$3.75M	Sell	126,700 -25,700	-17%	-$870K	0.45%	49
2019 Q4	$5.52M	Buy	152,400 +20,500	+16%	+$629K	0.48%	41
2019 Q3	$3.59M	Sell	131,900 -2,500	-2%	-$64.6K	0.31%	88
2019 Q2	$3.23M	Buy	134,400 +8,900	+7%	+$226K	0.32%	60
2019 Q1	$3.32M	Buy	125,500 +1,200	+1%	+$28.4K	0.3%	51
2018 Q4	$2.43M	Buy	124,300 +41,500	+50%	+$813K	0.29%	54
2018 Q3	$1.62M	Hold	82,800	–	–	0.21%	92
2018 Q2	$1.37M	Hold	82,800	–	–	0.17%	135
2018 Q1	$1.18M	Buy	+82,800	New	+$1.22M	0.16%	133

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Hillsdale Investment Management's HZNP Position: Q2 2021 in Review

Hillsdale Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 42,220 shares — an estimated $3.89M sold.

Hillsdale Investment Management first reported a position in HZNP in Q1 2018 and held it in 13 quarters. The position peaked at $5.52M in Q4 2019. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

Hillsdale Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
Hillsdale Investment Management sold 42,220 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $3.89M.
Hillsdale Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and held it in 13 quarters.
Hillsdale Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.52M in Q4 2019.
526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Hillsdale Investment Management's 13F filing for Q2 2021, filed 29 Jul 2021.